Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Biological Therapy Ilaris(R) Approved In US To Treat Children And Adults With CAPS, A Serious Life-Long Auto-Inflammatory Disease
The U.S. Food and Drug Administration (FDA) has approved Ilaris(R) (canakinumab) for the treatment of children and adults with cryopyrin-associated periodic syndrome (CAPS), which includes a number of rare, but life-long, auto-inflammatory disorders with debilitating symptoms and limited treatment options. The FDA granted priority review to Ilaris based on its potential to meet an important clinical need for patients with CAPS.
generic viagra online
International Collaboration Funds Stem Cell Research
The potential of using stem cells to treat Alzheimer"s disease and other illnesses will be investigated by Victorian and Californian researchers under a US$22 million (US$28.7 million) collaboration, Innovation Minister Gavin Jennings said recently.
News of the day
Opinion Piece Examines Efficacy Of Foreign Aid
"President Obama signaled recently a major shift in the way the United States tries to help poor countries," Philip Stevens, policy director at the International Policy Network, writes in a Providence Journal opinion piece, adding, "Whereas the Bush presidency pushed to spend enormous sums on individual high-profile diseases such as AIDS, Obama says he will broaden U.S. aid to improve health more generally." However, Stevens writes that the "$63 billion question remains (for that is the sum proposed by Obama): Is it likely to help improve health over the long term?" He adds, "Because far more people in poor countries die of preventable diseases like pneumonia than AIDS, the plan makes some sense. But, heartless as it seems, health care programs funded by foreign aid rarely if ever live up to the soaring rhetoric with which they are launched by politicians." According to Stevens, "[s]tudy after study shows that health aid makes almost no difference to mortality rates and health outcomes, despite the expenditure of billions." He adds, "In happier economic times, indefinitely financing state health care in Africa may have imparted a warm humanitarian glow to U.S. taxpayers. Now that times are harder, and it is clear such transfers rarely work, maybe it"s time to pare them right back." Stevens writes, "When governments become dependent on foreign s to maintain their activities, it drives a wedge between them and their citizens and allows corrupt and repressive governments to remain in power." It also "discourages governments from enacting the politically difficult reforms needed to promote economic development strengthening the rule of law, establishing property rights and opening markets," Stevens writes, adding, "Without improving prosperity, you can"t improve health care."He concludes, "Fortunately, the recession has accelerated recent declines in foreign aid. Congress still has to approve the funds so it has a chance to end subsidies to corrupt governments and being a new chapter for the world"s poorest people" (Stevens, Providence Journal, 5/17).
Public Health

Critical Appraisal Of Continuous Glucose Monitoring Technology Is Focus Of Diabetes Technology & Therapeutics Supplement

Continuous Glucose Monitoring (CGM) devices represent a critical step toward achieving automated glucose measurement, offering people with diabetes a promising new tool for maintaining optimal glucose control. A comprehensive review of this rapidly changing field, featuring the most recent research findings and critical analysis, is the focus of a special supplement of Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. The supplement is available free online at http://www.liebertonline.com/dia "CGM is still in its infancy, yet this technology is already becoming the standard of care," writes Satish K. Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics, and Professor of Medicine and Pediatrics from the University of Colorado Denver, in an editorial introducing the supplement. Over the past decade, "The annual healthcare costs related to diabetes care in the United States have increased significantly by 32%...to $174 billion," despite improvements in glucose control, Garg notes. Better methods are needed to prevent the long- and short-term complications associated with diabetes. This in-depth supplement provides a detailed presentation of the need for better glucose monitoring techniques, describes state-of-the-art CGM technology, and looks to the future and the ultimate goal of integrating CGM with an artificial pancreas to simulate normal blood glucose control systems in the body. Several articles focus on the challenges that CGM must still overcome, whether technical, practical, or economic. In the editorial, "Do We Really Need Continuous Glucose Monitoring?" Anne Peters, MD, from the University of Southern California Keck School of Medicine (Los Angeles), points out some of the drawbacks of current CGM technology: for example, the devices are "finicky and require care and calibration leading patients to use them infrequently"; "few physicians know how to interpret the data"; and "CGM devices have not been shown to reduce rates of severe hypoglycemia." Associate Editor Jay S. Skyler, MD, from the University of Miami Miller School of Medicine (Florida), reviews the history of CGM in an editorial entitled, "Continuous Glucose Monitoring: An Overview of Its Development." Eric Orzeck, MD, from Endocrinology Associates (Houston, TX), describes the need for better documentation, coding, and appeal procedures for use of CGM to improve insurance coverage, in the article, "Maximizing Reimbursement through Correct Coding Initiatives." In the commentary entitled, "Continuous Glucose Monitoring: Understanding Our Current Culture," Irl Hirsch, MD, from the University of Washington School of Medicine (Seattle), concludes that CGM, "is only a tool to help patients make better decisions about insulin and food. Until we have a closed-loop system or islet cell transplant, human behavior will continue to dictate the success of a patient with his or her diabetes control." Vicki Cohn Mary Ann Liebert, Inc./Genetic Engineering News


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009